ClinicalTrials.gg
WithdrawnNCT02172001Updated Sep 28, 2016

A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

A Phase 3 interventional study of Iron isomaltoside 1000 and Natrium Chloride 0,9% in Iron Deficiency Anemia, sponsored by Pharmacosmos A/S. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-28.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study design not adequate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
32nd of 32
0 · median 121
Phase 3
18 of 32
4 open now
Registered
6th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 32nd largest by enrollment, is one of 18 in phase 3, and was the 6th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate and compare the effect of iron isomaltoside 1000 to placebo in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be used.

Read the detailed description

IDA is highly prevalent in subjects and can have a substantial medical and quality of life (QoL) burden on the subjects and the treatment of these subjects includes replenishing lost iron. Oral iron administration is often used in the clinical practice at many clinics; however, oral iron may not be tolerated by all subjects. Hence, there is a need for an alternative iron treatment in subjects, who do not tolerate oral iron.

This study is planned to compare the efficacy and safety of iron isomaltoside 1000 with placebo in subjects with IDA and who are intolerant or unresponsive to oral iron therapy..

03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • IDA
  • Iron deficiency
  • iron deficiency anemia and who are intolerant or unresponsive to oral iron therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women ≥ 18 years having IDA caused by different aetiologies* such as ab-normal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy** for at least one month*** prior to study enrolment
  2. \< 11 g/dL
  3. TSAT \< 20 %
  4. S-ferritin \< 100 ng/mL
  5. Willingness to participate and signing the form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. \< 6 g/dL
  2. Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreat-ed vitamin B12 or folate deficiency, haemolytic anaemia)
  3. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and hae-mosiderosis)
  4. Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times )
  5. Active acute or chronic infections (assessed by clinical judgement supplied with white blood cells (WBC) and C-reactive protein (CRP))
  6. Body weight \< 50 kg
  7. Pregnant or nursing women. In order to avoid pregnancy, women of childbearing po-tential have to use adequate (e.g. intrauterine devices, hormonal contra-ceptives, or double barrier method) during the whole study period and 7 days after the last dosing
  8. History of multiple allergies
  9. Known to parenteral iron or any in the drug products
  10. Erythropoietin treatment within 8 weeks prior to the screening visit
  11. Other intravenous (IV) iron treatment or blood transfusion within 4 weeks prior to the screening visit
  12. Participation in any other interventional clinical study within 3 months prior to the screening
  13. Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside 1000

    Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg

    Drug: Iron isomaltoside 1000

  • Placebo comparator
    Placebo (NaCl 0,9%)

    Sodium Chloride. Dose: 100 ml or 5 ml

    Drug: Natrium Chloride 0,9%

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5

    Time frame: Week 1 to 5

Secondary outcomes

  1. Time to Hb ≥ 2 g/dL

    Time frame: Week 1 to 5

07

Study locations

1 site
  • Baltimore, Maryland 21237, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02172001
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Jun 24, 2014
Primary completion
Mar 2015
Last update
Sep 28, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion